Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 14Unknown 3Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 473Prostatic Neoplasms 423Neoplasms 384Multiple Myeloma 266Colorectal Neoplasms 257Lung Neoplasms 245Neoplasm Metastasis 234Melanoma 219Leukemia, Myeloid, Acute 193Ovarian Neoplasms 189Pancreatic Neoplasms 177Squamous Cell Carcinoma of Head and Neck 160Carcinoma, Renal Cell 146Recurrence 144Lymphoma 144Glioblastoma 142Lymphoma, Non-Hodgkin 136Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Leukemia, Lymphocytic, Chronic, B-Cell 123Brain Neoplasms 123Carcinoma, Hepatocellular 122Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Urinary Bladder Neoplasms 115Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Lymphoma, Large B-Cell, Diffuse 104Sarcoma 103Lymphoma, Follicular 100

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Fanconi Anemia, Complementation Group D1 × Clear all
NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

Beth Israel Deaconess Medical Center

Phase 2 Active not recruiting
114 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡